Development of a phospholipid nanoparticle-based volume expander for blood volume replacement and organ protection in hemorrhagic shock
Active Grant Awarded Last action
- Award ID
- R43HL186835
- Recipient
-
Vivacelle Bio Inc. UEI DFXZMMZ9BB21
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $313,906
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 20% complete
- Place of performance
- Kansas City, MO 64108, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute awarded Vivacelle Bio Inc. $313,906 on September 9, 2026, under Grant R43HL186835, funded through the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development of VBI-160, a phospholipid nanoparticle-based colloidal volume expander for blood volume replacement and organ protection in hemorrhagic shock. The project summary states that VBI-160 restores and sustains mean arterial pressure, reduces ischemia-reperfusion injury, and preserves clotting. It positions the product against crystalloids, which it describes as providing short-lived volume expansion and possibly causing tissue edema, and colloids, which it describes as impairing clotting and kidney function.
The recipient is Vivacelle Bio Inc. (UEI DFXZMMZ9BB21). Dollars obligated total $313,906. The period of performance runs from the September 9, 2026 award date to an ultimate completion date of August 31, 2027. Place of performance is Kansas City, MO 64108, USA. The source identifies no sub-recipients.
The parent program supports heart and vascular research across basic, translational, clinical, and population sciences, and it funds training to develop early-career investigators in those areas.
Description
- Abstract
- Hemorrhagic shock is a life-threatening condition caused by severe blood loss leading to inadequate oxygenation of cellular tissues. If left untreated, IT quickly leads to cardiac arrest, and is a leading cause of preventable death, accounting for up to 40% of civilian trauma and 90% of potentially preventable battlefield fatalities. Type-matched blood is the gold standard for resuscitation in hemorrhagic shock; however, IT is often unavailable during emergencies, particularly in low-resource and prehospital settings, due to type-matching requirements, low shelf life, and storage limitations. Even when available, blood transfusion carries risks such as ischemia-reperfusion injury (IRI), infection, respiratory distress, and multi-organ dysfunction, which can lead to long-term damage in survivors. Unfortunately, efforts to develop artificial substitutes for blood have failed due to serious side effects like oxidative stress and even increased mortality. In the absence of blood and its substitutes, FDA-approved volume expanders such as crystalloids (e.g., ringer's lactate) and colloids (e.g., albumin) are used to temporarily support circulation. However, crystalloids provide short-lived volume expansion and may cause tissue edema, while colloids do not provide volume expansion for much longer than crystalloids, and can also impair blood clotting and kidney function. Thus, there is an urgent, unmet need for a resuscitation fluid that is safe, effective in resource-limited settings, and restores blood pressure while preserving clotting and protecting against IRI. Vivacelle BIO INC. (VBI) is addressing this by developing VBI- 160, a phospholipid nanoparticle (PN)-based colloidal volume expander that restores and sustains mean arterial pressure (map), reduces IRI, and preserves clotting. Upon infusion, VBI-160'S colloids restore and maintain intravascular volume while also sequestering excess nitric oxide (no), a key driver of subsequent hemorrhagic shock pathology. In preliminary studies with RAT models, resuscitation with VBI-160 matched shed blood in total blood loss, bleed time and map elevation, while offering superior organ protection. Therefore, in this phase I sbir project, we aim to establish the stability profile, preclinical efficacy, and immunological and cognitive outcomes of VBI-160. In aim 1, we will characterize VBI-160 for physicochemical properties, sterility, no uptake/release, and shelf life. In aim 2, we will assess hemodynamic restoration efficacy of VBI-160 in a fixed-pressure hemorrhagic shock model, compared to shed blood and ringer's lactate, through serial blood analysis and terminal tissue assessment. Finally, we will evaluate the immunomodulatory and cognitive effects of VBI-160 through flow cytometry, elisa, and behavioral tests (aim 3). Successful completion of these aims will position VBI-160 for CMC manufacturing and subsequent clinical validation as a safe and effective resuscitation fluid for hemorrhagic shock that reduces dependence on donor blood in both civilian and battlefield care.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $313,906 |
Quick answers
Who received award R43HL186835?
R43HL186835 was awarded to Vivacelle Bio Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 9, 2026.
How much is award R43HL186835 worth?
$313,906 has been obligated on R43HL186835.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award